CRISPR-based gene editing shows promise in treating rare form of blindness

FHS
May 6, 2024
6:43 pm

About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine.

Benefits of Adjuvant RT for Early Breast Cancer Limited to First 10 Years

Adjuvant radiotherapy (RT) for early breast cancer protected against ipsilateral recurrence for 10 years after treatment but not thereafter, according to long-term follow-up from a

August 16, 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists Challenge Psychedelic Scheduling Bid – Psychedelic Alpha

Having abandoned two attempts at scheduling sets of psychedelics following pushback (as in the case of the five tryptamines and the earlier effort to schedule

November 19, 2024

How the Wegovy shortage is making life impossible for my patients — and for me

There is just not enough Wegovy. The current manufacturing shortage will eventually end, and those who have health insurance that covers Wegovy, plus the even

September 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.